---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-244709"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2021-08-12T23:59:59+00:00"
generated_at: "2026-06-29T13:44:17.790257+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio Q2 net loss $19.3M; cash $806.6M; NUV-422 trial expands

## Summary
- Net loss of $19.3M ($0.09/share) vs $8.6M loss ($0.10) in Q2 2020.
- Cash, cash equivalents and marketable securities $806.6M as of June 30.
- R&D expenses $14.0M, up from $7.3M, on higher clinical and preclinical costs.
- Phase 1/2 of NUV-422 expanded to glioblastoma, breast, and prostate cancers; Phase 1 data expected 2022.
- Appointed David C. Hanley as Chief Technical Operations Officer in June 2021.

## SEC filing metadata
- accession: 0001193125-21-244709
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2021-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312521244709/0001193125-21-244709-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312521244709/d212585d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-244709
- JSON: https://secwatch.observer/filing/0001193125-21-244709.json
- Plain text: https://secwatch.observer/filing/0001193125-21-244709.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.